A Swedish study finds that MG treatment leaves unsatisfactory symptomatic state for patients in almost half of cases

In Sweden, 1,077 patients with myasthenia gravis from the Genes and Environment in Myasthenia Gravis study (GEMG) cohort completed a 106-item self-administered questionnaire including the MG-ADL score. 

• almost half (47%) of the participants declared an unsatisfactory pathological state (MG-ADL score ≥3p), emphasizing the need to improve treatment. 
• obesity and female gender were associated with the highest risk of having residual symptoms on treatment.

The authors plan to conduct correlation studies between GEMG data and the Swedish National Prescription Drug Registry. 

 

Patient-Reported Symptom Severity in a Nationwide Myasthenia Gravis Cohort: Cross-sectional Analysis of the Swedish GEMG Study. Petersson M, Feresiadou A, Jons D et al. Neurology. 2021 Aug 10:10.1212/WNL.0000000000012604.